With Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For

WSW, NY, June 22nd, 2026, FinanceWire

The pharmaceutical industry is spending billions pursuing one idea: take injectable peptide medicines and turn them into pills. Novo Nordisk demonstrated the power of that model with oral semaglutide. Major pharmaceutical companies continue to spend aggressively on oral peptide technologies, betting that treatments once limited by injections can unlock dramatically larger markets when delivered in tablet form.

Entera Bio (NASDAQ: ENTX) has been pursuing that same vision in osteoporosis, and this morning the company announced what may be the most significant regulatory milestone in its history. Entera revealed that the FDA has provided positive feedback on the registrational Phase 3 protocol for EB613, the company's oral PTH(1-34) tablet for postmenopausal osteoporosis. The agency accepted Entera's proposed development strategy, including a single randomized, double-blind, placebo-controlled Phase 3 study in approximately 750 postmenopausal women using total hip bone mineral density at 12 months as the primary endpoint to support a future New Drug Application (NDA) submission.

For investors following the story, this was the question that has mattered most in recent months: Could Entera translate years of clinical development, positive Phase 2 data and recent ENDO 2026 momentum into a regulatory pathway capable of bringing EB613 to market?

The FDA's latest feedback suggests the answer is yes. The timing could hardly be more notable. Just days ago, Entera presented new EB613 data during a coveted Late-Breaking Oral Presentation at ENDO 2026, one of endocrinology's most important scientific meetings. The presentation demonstrated that the single-tablet version of EB613 achieved a pharmacokinetic and pharmacodynamic profile comparable to both injectable Forteo and the multi-tablet version that previously generated positive Phase 2 results.

Now, with FDA alignment on the registrational strategy, Entera appears to have both the product and the roadmap.

The opportunity in front of the company remains substantial. Osteoporosis affects an estimated 200 million women worldwide and is responsible for more than two million fractures annually in the United States alone. Despite the availability of highly effective anabolic therapies, adoption remains surprisingly low. The reason is straightforward: every currently approved anabolic treatment requires injection.

Entera's thesis has always been that one of the most effective classes of osteoporosis medicines could reach significantly more patients if delivered as a simple daily tablet. EB613 is an oral formulation of teriparatide, the same active hormone used in Eli Lilly's Forteo, one of the most successful anabolic osteoporosis drugs ever commercialized. Forteo generated approximately $1.7 billion

What makes today's announcement particularly important is the nature of the FDA feedback. The agency accepted Entera's proposed registrational study design and also agreed with the company's plan to continue following patients through an open-label extension study designed to provide additional safety, durability and treatment-sequencing data. Entera expects to initiate Phase 3 in late 2026 and anticipates topline results during the second half of 2028.

The broader backdrop only strengthens the story. In December 2025, the FDA qualified total hip bone mineral density as a validated surrogate endpoint for osteoporosis drug development, a landmark decision widely viewed as opening a new era for the field. Entera moved quickly to position EB613 at the forefront of that shift, submitting its streamlined Phase 3 protocol earlier this year and now securing positive FDA feedback on the proposed path forward.

The opportunity may also extend well beyond EB613. While the osteoporosis program remains the lead asset, Entera increasingly looks less like a single-asset biotech story and more like a platform company built around one of the most sought-after capabilities in modern drug development: oral peptides. Alongside EB613, the company is advancing EB612, an oral long-acting PTH tablet for hypoparathyroidism, as well as EB618, an oral GLP-1/glucagon peptide tablet for obesity and metabolic disease, both being developed in collaboration with OPKO Health. At ENDO 2026, Entera presented new data from both programs alongside its Late-Breaking Oral presentation for EB613, reinforcing the broader potential of its proprietary N-Tab platform. In an industry where billions of dollars continue to flow toward companies pursuing oral peptide technologies, Entera now has multiple programs advancing from the same underlying technology.

Clinical outcomes are never guaranteed, and EB613 must still successfully complete Phase 3 development and navigate regulatory review. However, Entera today looks very different than it did even a few months ago. The company now has positive Phase 2 data, a commercial single-tablet formulation supported by comparative clinical data, FDA alignment on its registrational strategy, and a clearly defined path toward a potential NDA submission for what could become the first oral anabolic treatment for osteoporosis.

For a company pursuing what many would consider a potential holy-grail opportunity in osteoporosis, while also advancing multiple additional oral peptide programs, the contrast is becoming increasingly difficult to ignore. As of yesterday, Entera's market capitalization remained reportedly below $60 million (as of friday's market close). The company now appears to have a Phase 3-ready lead asset, multiple shots on goal, a differentiated platform technology, and a regulatory pathway that is considerably clearer than it was just months ago.

Recent News Highlights from Entera (NASDAQ: ENTX)

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds 

Important Disclaimers and Disclosures: The author of this report, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Entera Bio Ltd. (the "Issuer") for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.

Contact